DIFICID
Peakfidaxomicin
Mechanism of Action
12.1 Mechanism of Action Fidaxomicin is an antibacterial drug [see ] . 12.2 Pharmacodynamics Fidaxomicin acts locally in the gastrointestinal tract on C. difficile . In a dose-ranging trial (N=48) of fidaxomicin using 50 mg, 100 mg, and 200 mg twice daily for 10 days, a dose-response relationship…
Macrolide Antibacterial
Indications (1)
Clinical Trials (5)
Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)
A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections
Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)
A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)
Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?
Loss of Exclusivity
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 7906489 | Mar 4, 2027 | U-2741 | |
| 8859510 | Jul 31, 2027 | U-2741 | |
| 7863249 | Jul 31, 2027 | Product | — |
| 7378508 | Jul 31, 2027 | SubstanceProduct | — |
| 7906489*PED | Sep 4, 2027 | — |